Logo image of BPMC

BLUEPRINT MEDICINES CORP (BPMC) Stock Fundamental Analysis

NASDAQ:BPMC - Nasdaq - US09627Y1091 - Common Stock - Currency: USD

129.46  +0.18 (+0.14%)

After market: 129.5 +0.04 (+0.03%)

Fundamental Rating

4

Overall BPMC gets a fundamental rating of 4 out of 10. We evaluated BPMC against 550 industry peers in the Biotechnology industry. BPMC may be in some trouble as it scores bad on both profitability and health. BPMC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BPMC had negative earnings in the past year.
In the past year BPMC has reported a negative cash flow from operations.
BPMC had negative earnings in 4 of the past 5 years.
In the past 5 years BPMC reported 4 times negative operating cash flow.
BPMC Yearly Net Income VS EBIT VS OCF VS FCFBPMC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

BPMC has a Return On Assets of -13.03%. This is amongst the best in the industry. BPMC outperforms 82.55% of its industry peers.
BPMC has a Return On Equity of -45.52%. This is in the better half of the industry: BPMC outperforms 67.63% of its industry peers.
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROIC N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
BPMC Yearly ROA, ROE, ROICBPMC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

BPMC's Gross Margin of 96.48% is amongst the best of the industry. BPMC outperforms 96.22% of its industry peers.
BPMC's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for BPMC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
BPMC Yearly Profit, Operating, Gross MarginsBPMC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
BPMC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BPMC has been increased compared to 5 years ago.
The debt/assets ratio for BPMC is higher compared to a year ago.
BPMC Yearly Shares OutstandingBPMC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BPMC Yearly Total Debt VS Total AssetsBPMC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 3.51 indicates that BPMC is not in any danger for bankruptcy at the moment.
BPMC has a Altman-Z score of 3.51. This is in the better half of the industry: BPMC outperforms 74.10% of its industry peers.
BPMC has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
BPMC's Debt to Equity ratio of 1.01 is on the low side compared to the rest of the industry. BPMC is outperformed by 76.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Altman-Z 3.51
ROIC/WACCN/A
WACC10.27%
BPMC Yearly LT Debt VS Equity VS FCFBPMC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

BPMC has a Current Ratio of 2.80. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.80, BPMC is not doing good in the industry: 66.73% of the companies in the same industry are doing better.
A Quick Ratio of 2.75 indicates that BPMC has no problem at all paying its short term obligations.
BPMC has a Quick ratio of 2.75. This is in the lower half of the industry: BPMC underperforms 65.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.75
BPMC Yearly Current Assets VS Current LiabilitesBPMC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

BPMC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.24%, which is quite impressive.
The Revenue has grown by 99.14% in the past year. This is a very strong growth!
Measured over the past years, BPMC shows a very strong growth in Revenue. The Revenue has been growing by 50.23% on average per year.
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%

3.2 Future

The Earnings Per Share is expected to grow by 28.63% on average over the next years. This is a very strong growth
BPMC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.27% yearly.
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BPMC Yearly Revenue VS EstimatesBPMC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
BPMC Yearly EPS VS EstimatesBPMC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

BPMC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 131.18, which means the current valuation is very expensive for BPMC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BPMC indicates a rather cheap valuation: BPMC is cheaper than 87.77% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BPMC to the average of the S&P500 Index (35.78), we can say BPMC is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 131.18
BPMC Price Earnings VS Forward Price EarningsBPMC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPMC Per share dataBPMC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

BPMC's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as BPMC's earnings are expected to grow with 46.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.32%
EPS Next 3Y46.02%

More info and screens

0

5. Dividend

5.1 Amount

BPMC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (7/17/2025, 8:06:04 PM)

After market: 129.5 +0.04 (+0.03%)

129.46

+0.18 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners109.31%
Inst Owner Change-0.75%
Ins Owners0.84%
Ins Owner Change-168.09%
Market Cap8.37B
Analysts68
Price Target132.96 (2.7%)
Short Float %2.61%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.05%
Min EPS beat(2)-38.05%
Max EPS beat(2)-10.05%
EPS beat(4)2
Avg EPS beat(4)0.22%
Min EPS beat(4)-38.05%
Max EPS beat(4)39.24%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)9
Avg EPS beat(12)6.42%
EPS beat(16)11
Avg EPS beat(16)-9.61%
Revenue beat(2)0
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-5.77%
Max Revenue beat(2)-1.61%
Revenue beat(4)1
Avg Revenue beat(4)5.58%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)30.77%
Revenue beat(8)5
Avg Revenue beat(8)10.01%
Revenue beat(12)8
Avg Revenue beat(12)15.3%
Revenue beat(16)11
Avg Revenue beat(16)15.01%
PT rev (1m)0.02%
PT rev (3m)3.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-36.4%
EPS NY rev (1m)0%
EPS NY rev (3m)23.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 131.18
P/S 14.89
P/FCF N/A
P/OCF N/A
P/B 24.47
P/tB 24.47
EV/EBITDA N/A
EPS(TTM)-3.22
EYN/A
EPS(NY)0.99
Fwd EY0.76%
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS8.69
BVpS5.29
TBVpS5.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.48%
FCFM N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.61%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.75
Altman-Z 3.51
F-Score3
WACC10.27%
ROIC/WACCN/A
Cap/Depr(3y)80.73%
Cap/Depr(5y)67.67%
Cap/Sales(3y)3.9%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%
EBIT growth 1Y60.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.02%
EBIT Next 3Y49.05%
EBIT Next 5Y35.74%
FCF growth 1Y69.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.45%
OCF growth 3YN/A
OCF growth 5YN/A